Skip to main content

Advertisement

SpringerLink
Log in

Influenzaschutzimpfung

Influenza vaccination

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Die Schutzimpfung gegen die Influenza wird von der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI) für breite Bevölkerungsgruppen empfohlen. Neben der klassischen inaktivierten trivalenten Spaltvakzine stehen heute weitere Impfstoffvarianten zur Verfügung (lebend-attenuierter Impfstoff, quadrivalente inaktiverte Spaltvakzine, adjuvantierte Vakzine, virosomale Vakzine, intradermal zu applizierende Vakzine). Die Verträglichkeit der verschiedenen Vakzinen ist gut, und ernsthafte Nebenwirkungen sind ausgesprochen selten. Die Schutzwirkung gegenüber einer Influenzainfektion ist für die größte Zahl der betroffenen Personen ausreichend. Weitere Daten zu der Frage, ob auch klinische Ereignisse (Pneumonie, Hospitalisierung, Tod) durch die Impfung verhindert werden können, sind jedoch nach wie vor wünschenswert.

Abstract

Influenza vaccination is recommended by the Standing Vaccination Committee (STIKO) at the Robert Koch Institute (RKI) for a broad range of population groups. Besides the classical inactivated trivalent split vaccine, a number of other vaccines are currently available (e.g. live attenuated vaccine, quadrivalent inactivated split vaccines, vaccines with adjuvant formulations, virosomal vaccines and intradermal injectable vaccines). The safety and tolerability of all available vaccines is generally good and serious side effects are extremely rare. The efficacy of influenza vaccination against influenza infections has been demonstrated for the majority of persons. However, effectiveness data for clinically relevant endpoints (e.g. pneumonia, hospitalization and death) are still needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171–4175

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931–939

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Robert Koch-Institut (2013) Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2013 Epidemiol Bull 34:313–344

  4. Centers for Disease Control and Prevention (2013) Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices – United States, 2013–2014. MMWR Recomm Rep 62:1–43

    Google Scholar 

  5. Nicoll A, Tsolova S (2008) Guidance priority risk groups for influenza vaccination. http://www.ecdc.europa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf

  6. Poethko-Muller C, Schmitz R (2013) Vaccination coverage in German adults: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:845–857

    Article  CAS  PubMed  Google Scholar 

  7. Kieninger D et al (2013) Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged > = 18 years. BMC Infect Dis 13:343

    Article  PubMed Central  PubMed  Google Scholar 

  8. Domachowske JB et al (2013) A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis 207:1878–1887

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Reed C et al (2012) Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30:1993–1998

    Article  PubMed  Google Scholar 

  10. Wutzler P, Hardt R, Knuf M, Wahle K (2013) Zielgruppenspezifische Wahl des Impfstoffes bei der Grippeimpfung. Dtsch Arztebl Int 110:793–798

    PubMed Central  PubMed  Google Scholar 

  11. Keitel WA et al (2006) Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166:1121–1127

    Article  PubMed  Google Scholar 

  12. Huckriede A et al (2005) The virosome concept for influenza vaccines. Vaccine 23(Suppl 1):26–38

    Article  Google Scholar 

  13. Salleras L et al (2006) Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3–14 years: a prospective cohort study. Vaccine 24:6638–6642

    Article  CAS  PubMed  Google Scholar 

  14. Esposito S et al (2012) The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥ 6 to < 36 months: data from a randomized, Phase III study. Vaccine 30:7005–7012

    Article  CAS  PubMed  Google Scholar 

  15. Vesikari T et al (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406–1416

    Article  CAS  PubMed  Google Scholar 

  16. Bautista E et al (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362:1708–1719

    Article  PubMed  Google Scholar 

  17. Wijnans L et al (2013) The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31:1246–1254

    Article  PubMed  Google Scholar 

  18. Szakacs A, Darin N, Hallbook T (2013) Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80:1315–1321

    Article  PubMed  Google Scholar 

  19. Heier MS et al (2013) Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 14:867–871

    Article  CAS  PubMed  Google Scholar 

  20. Barker CI, Snape MD (2014) Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 14:227–238

    Article  PubMed  Google Scholar 

  21. Atmar RL, Patel SM, Keitel WA (2010) Intanza(®): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 9:1399–1409

    Article  CAS  PubMed  Google Scholar 

  22. Young F, Marra F (2011) A systematic review of intradermal influenza vaccines. Vaccine 29:8788–8801

    Article  CAS  PubMed  Google Scholar 

  23. Ansaldi F et al (2012) Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 30:2908–2913

    Article  CAS  PubMed  Google Scholar 

  24. Belshe RB et al (2010) Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses 4:141–145

    Article  PubMed  Google Scholar 

  25. Jefferson T et al (2010) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 7:CD001269

    PubMed  Google Scholar 

  26. Jefferson T et al (2012) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 8:CD004879

    PubMed  Google Scholar 

  27. Michiels B et al (2011) A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 29:9159–9170

    Article  PubMed  Google Scholar 

  28. Rivetti D et al (2006) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3:CD004876

    PubMed  Google Scholar 

  29. Gross PA et al (1995) The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518–527

    Article  CAS  PubMed  Google Scholar 

  30. Beck CR et al (2012) Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 206:1250–1259

    Article  PubMed  Google Scholar 

  31. Cheuk DK et al (2011) Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 3:CD006505

    PubMed  Google Scholar 

  32. Jefferson T et al (2010) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2:Cd004876

    PubMed  Google Scholar 

  33. Thomas RE, Jefferson T, Lasserson TJ (2010) Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2:Cd005187

    PubMed  Google Scholar 

  34. Osterholm MT et al (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36–44

    Article  PubMed  Google Scholar 

  35. Christenson B et al (2001) Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 357:1008–1011

    Article  CAS  PubMed  Google Scholar 

  36. Hedlund J et al (2003) Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 21:3906–3911

    Article  CAS  PubMed  Google Scholar 

  37. Tessmer A et al (2011) Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 38:147–153

    Article  CAS  PubMed  Google Scholar 

  38. Rowhani-Rahbar A, Klein NP, Baxter R (2012) Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Rev Vaccines 11:973–984

    Article  CAS  PubMed  Google Scholar 

  39. Manzoli L et al (2012) Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 8:851–862

    Article  PubMed Central  PubMed  Google Scholar 

  40. Stowe J et al (2009) Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 169:382–388

    Article  PubMed  Google Scholar 

  41. Kwong JC et al (2013) Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 13:769–776

    Article  CAS  PubMed  Google Scholar 

  42. Touma Z, Gladman DD, Urowitz MB (2013) Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 25:164–170

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenskonflikt. T. Schaberg und M.W. Pletz haben die folgenden pharmazeutischen Unternehmen beraten oder Honorare für Vorträge von diesen erhalten: Novartis, GSK, AstraZeneca, Pfizer, SKB, Sanofi Pasteur. Der Beitrag enthält keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg, Elise-Averdiek-Str. 17, 27356, Rotenburg, Deutschland

    T. Schaberg

  2. Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland

    M.W. Pletz

Authors
  1. T. Schaberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.W. Pletz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Schaberg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schaberg, T., Pletz, M. Influenzaschutzimpfung. Pneumologe 11, 493–499 (2014). https://doi.org/10.1007/s10405-014-0788-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-014-0788-6

Schlüsselwörter

Keywords

Search

Navigation